Literature DB >> 2197725

The thalassemia syndromes: molecular basis and prenatal diagnosis in 1990.

H H Kazazian1.   

Abstract

In this review I have outlined the molecular basis and prenatal diagnosis of alpha-thalassemia and then concentrated on the state of our knowledge of the molecular basis of beta-thalassemia and its prenatal diagnosis. I discussed the improved but more complicated genetic counselling now available as a result of our increased knowledge of the effects of various defects in the beta-globin gene. Our knowledge of the heterogeneous molecular basis of the thalassemia syndromes has become very impressive and it is hoped that effective therapy will soon follow. For the present, however, prevention of the birth of affected children is the most effective means of reducing the suffering associated with the thalassemia syndromes, and prevention of this type is succeeding in many parts of the world, including North America.

Entities:  

Mesh:

Year:  1990        PMID: 2197725

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  40 in total

1.  The molecular basis of beta-thalassemia in Turkey.

Authors:  A N Başak; H Ozçelik; A Ozer; A Tolun; M Aksoy; L Ağaoğlu; F Ridolfi; L Ulukutlu; N Akar; A Gürgey
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

2.  Prevention of thalassemia: a necessity in India.

Authors:  I C Verma; V P Choudhry; P K Jain
Journal:  Indian J Pediatr       Date:  1992 Nov-Dec       Impact factor: 1.967

3.  The polymerase chain reaction: An overview and development of diagnostic PCR protocols at the LCDC.

Authors: 
Journal:  Can J Infect Dis       Date:  1991

4.  Spectrin Rouen (beta 220-218), a novel shortened beta-chain variant in a kindred with hereditary elliptocytosis. Characterization of the molecular defect as exon skipping due to a splice site mutation.

Authors:  M Garbarz; W T Tse; P G Gallagher; C Picat; M C Lecomte; F Galibert; D Dhermy; B G Forget
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

5.  A novel -32 (C-A) mutant identified in amplified genomic DNA of a Chinese beta-thalassemic patient.

Authors:  L I Lin; K S Lin; K H Lin; T Y Cheng
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

6.  Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis.

Authors:  P W Miller; A Hamosh; M Macek; P A Greenberger; J MacLean; S M Walden; R G Slavin; G R Cutting
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

7.  Carrier detection and prenatal diagnosis of alpha-thalassemia of Southeast Asian deletion by polymerase chain reaction.

Authors:  T M Ko; L H Tseng; F J Hsieh; P M Hsu; T Y Lee
Journal:  Hum Genet       Date:  1992-01       Impact factor: 4.132

8.  Molecular characterization of mild-to-moderate hemophilia A: detection of the mutation in 25 of 29 patients by denaturing gradient gel electrophoresis.

Authors:  M Higuchi; S E Antonarakis; L Kasch; J Oldenburg; E Economou-Petersen; K Olek; M Arai; H Inaba; H H Kazazian
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

9.  The thalassemias and health care in Canada: a place for genetics in medicine.

Authors:  D H Chui; S C Wong; C R Scriver
Journal:  CMAJ       Date:  1991-01-01       Impact factor: 8.262

10.  The great heterogeneity of thalassemia molecular defects in Sicily.

Authors:  A Giambona; P Lo Gioco; M Marino; I Abate; R Di Marzo; M Renda; F Di Trapani; F Messana; S Siciliano; P Rigano
Journal:  Hum Genet       Date:  1995-05       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.